首页> 美国卫生研究院文献>Pathogens >HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China
【2h】

HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China

机译:抗逆转录病毒治疗中断期间下一代测序检测的HIV耐药性突变检测

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Patients with antiretroviral therapy interruption have a high risk of virological failure when re-initiating antiretroviral therapy (ART), especially those with HIV drug resistance. Next-generation sequencing may provide close scrutiny on their minority drug resistance variant. A cross-sectional study was conducted in patients with ART interruption in five regions in China in 2016. Through Sanger and next-generation sequencing in parallel, HIV drug resistance was genotyped on their plasma samples. Rates of HIV drug resistance were compared by the McNemar tests. In total, 174 patients were included in this study, with a median 12 (interquartile range (IQR), 6–24) months of ART interruption. Most (86.2%) of them had received efavirenz (EFV)evirapine (NVP)-based first-line therapy for a median 16 (IQR, 7–26) months before ART interruption. Sixty-one (35.1%) patients had CRF07_BC HIV-1 strains, 58 (33.3%) CRF08_BC and 35 (20.1%) CRF01_AE. Thirty-four (19.5%) of the 174 patients were detected to harbor HIV drug-resistant variants on Sanger sequencing. Thirty-six (20.7%), 37 (21.3%), 42 (24.1%), 79 (45.4%) and 139 (79.9) patients were identified to have HIV drug resistance by next-generation sequencing at 20% (v.s. Sanger, p = 0.317), 10% (v.s. Sanger, p = 0.180), 5% (v.s. Sanger, p = 0.011), 2% (v.s. Sanger, p < 0.001) and 1% (v.s. Sanger, p < 0.001) of detection thresholds, respectively. K65R was the most common minority mutation, of 95.1% (58/61) and 93.1% (54/58) in CRF07_BC and CRF08_BC, respectively, when compared with 5.7% (2/35) in CRF01_AE (p < 0.001). In 49 patients that followed-up a median 10 months later, HIV drug resistance mutations at >20% frequency such as K103N, M184VI and P225H still existed, but with decreased frequencies. The prevalence of HIV drug resistance in ART interruption was higher than 15% in the survey. Next-generation sequencing was able to detect more minority drug resistance variants than Sanger. There was a sharp increase in minority drug resistance variants when the detection threshold was below 5%.
机译:抗逆转录病毒治疗中断的患者在重新启动抗逆转录病毒治疗(ART),尤其是具有艾滋病毒抗药性的患者时具有高风险学失败的风险。下一代测序可以在少数耐药性变体上提供密切的审查。在2016年中国五个地区的艺术中断患者中进行了横截面研究。通过Sanger和下一代测序并行,艾滋病毒耐药性在其血浆样品上进行基因分型。通过McNemar测试比较了HIV耐药率的速率。本研究总共包括174名患者,中位数12(赤脚范围(IQR),6-24)个月的艺术中断。其中大多数(86.2%)已接受efaviraz(EFV)/ Nevirapine(NVP),用于艺术中断前16个月(IQR,7-26)个月的中位数16(IQR,7-26)个月。六十一(35.1%)患者有CRF07_BC HIV-1菌株,58(33.3%)CRF08_BC和35(20.1%)CRF01_AE。检测到174名患者的344名(19.5%)患者对Sanger测序的含HIV耐药性变种。 37%(20.7%),37(21.3%),42(24.1%),79(45.4%)和139名(79.9%)和139名(79.9%)患者通过下一代测序鉴定为20%(VS Sanger, p = 0.317),10%(Vs sanger,p = 0.180),5%(vs sanger,p = 0.011),2%(vs sanger,p <0.001)和1%(vs sanger,p <0.001)检测分别阈值。 K65R分别是最常见的少数突变,分别在CRF07_BC和CRF08_BC中分别为95.1%(58/61)和93.1%(54/58),而CRF01_AE中的5.7%(2/35)(P <0.001)。在49名患者中随访10个月后,HIV耐药性突变> 20%频率,如K103N,M184VI和P225H仍然存在,但频率降低。艾滋病毒抗药性中断的患病率在调查中高于15%。下一代测序能够检测比Sanger更多的少数耐药性变体。当检测阈值低于5%时,少数抗性耐药变体急剧增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号